Find out how Magmaris can benefit your daily practice

magmaris TLF

Clinical Study Highlights

*Based on BIOSOLVE-II, -II/-III and -IV, for patient populations see study details;
1. According to the Magnesium 2,000 program; 2. Bennett J. Safety and Efficacy of the Resorbable Magnesium Scaffold, Magmaris in a Real-World Setting – 24-month Follow-up of the Full Cohort (2066 subjects) of the BIOSOLVE-IV Registry. Presented at: TCT, September 2022, Boston, USA. NCT02817802

Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
​​​​​​​Magmaris is currently not available in the US.

© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.